The Obesity Podcast Ep.2: Medications, Mechanisms & the “Gateway Effect” discussion of incretin-based medications | J&J MedTech

Joined by Professor David Cummings (University of Washington, Seattle), Paulina and Marco explore the revolutionary impact of new incretin-based medications such as semaglutide and tirzepatide. Cummings explains their origins in metabolic surgery research, how GLP-1 and GIP mechanisms work, and why the field has shifted dramatically after decades of weak pharmacological options. He addresses surgeons’ fears that drugs might replace operations, reframing them as complementary tools that can expand patient access and even drive more people into treatment pathways (the “gateway effect”). The discussion highlights unanswered questions-timing of drug use around surgery, long-term cost-effectiveness, and tailoring medications to individuals-but concludes that surgery and medications together form a stronger, multidisciplinary strategy against obesity.